


Cross-strain HIV therapeutic vaccine for all geographical regions

A series of chimeric immunogenic polypeptides developed based on the HIVconsv methodology, capable of inducing robust, effective and cross-strain immunity to HIV, is available and tested in clinical trials.

Applications: HIV therapeutic or prophylactic vaccine



Features	Benefits
First-generation HIVconsvX conserved vaccines delivered by simian adenovirus ChAdV63 and poxvirus MVA showed high immunogenicity across 8 trials in UK, EU and Africa	Wealth of clinical data and knowledge in the development of HIV cross-strain vaccines; Successfully elicit protective potential of killer T cells targeting regions in HIVconsvX
Second-generation tHIVconsvX with conserved protein regions common to global variants delivered by simian adenovirus ChAdOx1 and poxvirus MVA are being tested in a heterologous prime-boost regimen	HIVconsvX vaccine with maximum HIV epitope match that protect against all HIV escape variants; ChAdOx1, a platform used in the Oxford/Astra-Zeneca vaccine for SARS-CoV2, a licensed and proven effective vaccine
Immunogen delivery applicable to other vaccine platforms e.g. RNA	Viable vaccine modalities for effective therapeutic or prophylactic use

Patented and Available for

- Co-development
- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.